|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Further support for a Cretaceous age for the feathered-dinosaur beds of Liaoning,China:New ^(40)Ar/^(39)Ar dating of the Yixian and Tuchengzi Formations显示文摘We report new 40Ar/39Ar dating results ob-tained from total fusion and incremental-heating analyses of sanidine and biotite from three tuffs found interbedded within the fossil-bearing deposits of Liaoning, northeast China. The first is a new sample of the Bed 6 Sihetun tuff from the Yixian Formation, previously dated by our team as middle Early Cretaceous, and recently considered by Lo et al., partially reset due to metamorphism from a nearby ba-saltic sill. The second is the Yixian Bed 9 tuff from Heng-daozi considered by Lo et al. to be unaffected by metamor-phism and whose age, based on total fusion 40Ar/39Ar dating of biotite, argues for a Jurassic age for the Yixian Formation. The third tuff is a previously undated tuff from the upper part of the underlying Tuchengzi Formation. Single crystal total fusion 40Ar/39Ar analyses of the Sihetun sanidine showed homogeneous radiogenic Ar, Ca/K ratios, excellent reproducibility and gave a mean age of 125.0 ± 0.18 (1SD) ± 0.04 (SE) Ma. Single sanidine | C. C. Swisher III, WANG Xiaolin, ZHOU Zhonghe, WANG Yuanqing, JIN Fan, ZHANG Jiangyong , XU Xing, ZHANG Fucheng & WANG YuanDepartment of Geological Sciences, Wright Labs, Rutgers University, Piscataway, New Jersey 08854, USA (e-mail: cswish@rutgers. rci.e | 2002 | Chinese Science Bulletin2002，47，2： | 83 |
| 2 | Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer显示文摘AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. RESULTS: Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 mo (range: 3-21 mo), all 6 evaluable patients achieved complete response. Of them, 2 developed localrecurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fi stula. CONCLUSION: Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome. | Shu-Lian Wang Zhongxing Liao Helen Liu( Jaffer Ajani Stephen Swisher James D Cox Ritsuko Komaki | 2006 | World Journal of Gastroenterology2006，12，34： | 27 |
| 3 | Predictive biomarkers in precision medicine and drug development against lung cancer显示文摘The molecular characterization of various cancers has shown that cancers with the same origins,histopathologic diagnoses,and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause tumorigenesis.A number of cancer driver genes with functional abnormalities that trigger malignant transformation and that are required for the survival of cancer cells have been identified.Therapeutic agents targeting some of these cancer drivers have been successfully developed,resulting in substantial improvements in clinical symptom amelioration and outcomes in a subset of cancer patients.However,because such therapeutic drugs often benefit only a limited number of patients,the successes of clinical development and applications rely on the ability to identify those patients who are sensitive to the targeted therapies.Thus,biomarkers that can predict treatment responses are critical for the success of precision therapy for cancer patients and of anticancer drug development.This review discusses the molecular heterogeneity of lung cancer pathogenesis;predictive biomarkers for precision medicine in lung cancer therapy with drugs targeting epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK),c-ros oncogene 1 receptor tyrosine kinase[ROSl),and immune checkpoints;biomarkers associated with resistance to these therapeutics;and approaches to identify predictive biomarkers in anticancer drug development.The identification of predictive biomarkers during anticancer drug development is expected to greatly facilitate such development because it will increase the chance of success or reduce the attrition rate.Additionally,such identification will accelerate the drug approval process by providing effective patient stratification strategies in clinical trials to reduce the sample size required to demonstrate clinical benefits. | Bingliang Fang Reza J Mehran John V Heymach Stephen G Swisher | 2015 | Chinese Journal of Cancer2015，34，7： | 5 |
| 4 | Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis显示文摘 | Nirav Thosani Harvinder Singh Asha Kapadia Nobuo Ochi Jeffrey H. Lee Jaffer Ajani Stephen G. Swisher Wayne L. Hofstetter Sushovan Guha Manoop S. Bhutani | 2012 | Gastrointestinal Endoscopy2012，，2： | 3 |
| 5 | Review of metals and binary oxides as sorbents for removing sulfur from coal-derived gases显示文摘 | Swisher J H Schwerdtfeger K | 1992 | Journal of Materials Engineering and Performance1992，1，3： | 1 |
| 6 | Occult canver of the fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy a case for recommending hysterectomy at surgical prophylaxis显示文摘 | Paley PI Swisher EM Garcia RL | 2001 | Gynecol Oncol2001，80，： | 1 |
| 7 | Treatment outcomes of resected esophageal cancer显示文摘 | Hofstetter Wayne MD Swisher | 2002 | Annals of Surgery2002，236，3： | 1 |
| 8 | Clinical out- comes after platelet transfusions in patients with throm- botic thrombocytopenic purpura 显示文摘 | Swisher KK Terrell DR Vesely SK | 2009 | Transfusion2009，49，5： | 1 |
| 9 | Induction of p53 regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (NGN 201) and radiation therapy显示文摘 | SWISHER S G ROTHJ A KAMAKI R | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 10 | Management of intrathoracic leaks following esophagectomy 显示文摘 | Martin LW Hofstetter W Swisher SG | 2006 | Adv Surg2006，40，： | 1 |
| 11 | Detection of the HFA protein in urine as a biomarker for ovarian neo- plasms显示文摘 | Hellstrom I Heagerty P J Swisher EM | 2010 | Cancer Lett2010，296，1： | 1 |
| 12 | Cretaceous age for the feathered dinosaurs of Liaoning, China显示文摘 | Swisher C C Wang Y Q Wang X L | 1999 | Nature1999，400，： | 1 |
| 13 | Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer显示文摘 | Nemunaitis J Swisher S G Timmons T | 2000 | J Clin Oncol2000，18，3： | 1 |
| 14 | Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer显示文摘 | Nemunaitis J Swisher SG Timmons T | | 0，，03： | 1 |
| 15 | A Multicenter Study of Survival After Neoadjuvant Radiotherapy/Chemotherapy and Esophagectomy for ypT0N0M0R0 Esophageal Cancer显示文摘 | D. Vallb?hmer Arnulf H. H?lscher S. DeMeester T. DeMeester J. Salo J. Peters T. Lerut S. G. Swisher W. Schr?der E. Bollschweiler W. Hofstetter | 2010 | Annals of Surgery2010，，5： | 1 |
| 16 | Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the puget sound oncology consor- tium显示文摘 | Puget Sound Oncology Consortium Swisher EM Swensen RE | 2010 | Gynecol Oncol2010，26，12： | 1 |
| 17 | 查看详情显示文摘 | Blicke F. F Swisher R. D | | 0，，： | 1 |
| 18 | Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy显示文摘 | Swisher SG Roth JA Komaki R | | 0，，01： | 1 |
| 19 | Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura显示文摘 | SWISHER K K TERRELL D R VESELY S K | | 0，，05： | 1 |
| 20 | Outpatient management ofmalignantpleural effusion by achronic indwelling pleural catheter 显示文摘 | Putnam JB Jr Walsh GL Swisher SG | 2000 | Ann Thorac Surg2000，69，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员